Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Sharkey

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Infectious Diseases|April 30, 2002
Two long terminal repeat circles and persistent HIV-1 replicationM E Sharkey, M Stevenson
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|August 1, 1996
Matrix metalloproteinase expression during mouse peri-implantation developmentM E Sharkey, R R Adler, G L Nieder, et al.
Nature Medicine|December 10, 1998
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplificationV M Hirsch, M E Sharkey, C R Brown, et al.
Nature Medicine|December 29, 1999
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapyM E Sharkey, I Teo, T Greenough, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Infectious Diseases|April 30, 2002
Two long terminal repeat circles and persistent HIV-1 replicationM E Sharkey, M Stevenson
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|August 1, 1996
Matrix metalloproteinase expression during mouse peri-implantation developmentM E Sharkey, R R Adler, G L Nieder, et al.
Nature Medicine|December 10, 1998
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplificationV M Hirsch, M E Sharkey, C R Brown, et al.
Nature Medicine|December 29, 1999
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapyM E Sharkey, I Teo, T Greenough, et al.
Pageof 1